Form 6-K AURORA CANNABIS INC For: May 20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Harry and Meghan surprised by King Charles' letter on their status
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Aurora Cannabis (ACB:CN) (ACB) PT Raised to Cdn$27 at Cantor Fitzgerald; Positive on Reliva Deal
May 21, 2020 8:18 AM EDTCantor Fitzgerald analyst Pablo Zuanic raised the price target on Aurora Cannabis (ACB:CN) (NYSE: ACB) to Cdn$27.00 (from Cdn$22.00) while maintaining an Overweight rating after the company agreed to acquire Reliva.
The analyst commented, "ACB proved last Thursday (5/14) that it is making great strides with its reset (divestitures, cost cuts, cash flow improvement), and played down the risk of further dilution. Over the past 90 days into the print, the stock had been... More
